Comprehensive analysis of sickle β-thalassemia genotypes and their associated HbA levels in France.

Blood Cells Mol Dis

Service de Biochimie et de Biologie Moléculaire, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Bron, France; Laboratoire interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Team « Vascular Biology and Red Blood Cell » Université Claude Bernard Lyon 1, Université d

Published: May 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

We retrospectively reviewed the clinical records of 228 HbS/β-thal patients. The different genotypes were distributed into three groups according to their mean residual HbA levels: <10 % (group 1; n = 22), between 10 and 20 % (group 2; n = 175) and > 20 % (group 3; n = 31). Routine red blood cells and hemoglobin parameters were compared between the three groups. Sixteen different sickle β-thal genotypes were identified but only four of them were associated with a residual HbA level below 10 %. Patients of this group exhibited a more severe anemia (Hb < 10 g/dL; reticulocytes >200 G/L) compared to the two other groups. However, no difference could be observed on those parameters between patients of group 2 and 3, as well as for the main RBC parameters. According to our study, >80 % of the sickle β-thalassemia patients in France have a residual HbA level beyond 10 % and a mild to moderate anemia. Only four β-thal variations (all affecting the splicing process) would lead to a potentially severe SCD syndrome in association with HbS (HbA < 10 %) but this result should be confirmed in a prospective clinical study.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcmd.2025.102923DOI Listing

Publication Analysis

Top Keywords

residual hba
12
sickle β-thalassemia
8
hba levels
8
three groups
8
hba level
8
level 10 %
8
patients group
8
comprehensive analysis
4
analysis sickle
4
β-thalassemia genotypes
4

Similar Publications

In Situ Polymerization Controlled Growth of Perovskite via Benzoic Acid Crosslinking Agent for Highly Efficient and Mechanically Robust Flexible Perovskite Solar Cell.

Adv Sci (Weinh)

July 2025

College of Physics and Optoelectronics Engineering, Shanxi Key Lab of Photovoltaic Technology and Application, Key Lab of Advanced Transducers and Intelligent Control System, Taiyuan University of Technology, Taiyuan, 030024, China.

The controlled growth of perovskite on flexible substrates is essential for achieving highly efficient and stable flexible perovskite solar cells (FPSCs). Herein, a novel strategy of 4-hydroxybenzoic acid (4-HBA) is developed to regulate the crystallization dynamics of perovskite. In situ cross-linking network of 4-HBA provided an excellent formwork for high-quality perovskite growth by controlling excessive nucleation and prolonging crystallization.

View Article and Find Full Text PDF

Comprehensive analysis of sickle β-thalassemia genotypes and their associated HbA levels in France.

Blood Cells Mol Dis

May 2025

Service de Biochimie et de Biologie Moléculaire, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Bron, France; Laboratoire interuniversitaire de Biologie de la Motricité (LIBM) EA7424, Team « Vascular Biology and Red Blood Cell » Université Claude Bernard Lyon 1, Université d

We retrospectively reviewed the clinical records of 228 HbS/β-thal patients. The different genotypes were distributed into three groups according to their mean residual HbA levels: <10 % (group 1; n = 22), between 10 and 20 % (group 2; n = 175) and > 20 % (group 3; n = 31). Routine red blood cells and hemoglobin parameters were compared between the three groups.

View Article and Find Full Text PDF

Aims/hypothesis: Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, shows some promise in alleviating beta cell stress and preserving beta cell function in preclinical studies of type 1 diabetes. The aim of this phase 2, placebo-controlled, double-blinded, randomised clinical trial was to investigate the efficacy and safety of fenofibrate in adults and adolescents with newly diagnosed type 1 diabetes.

Methods: We enrolled 58 individuals (aged 16 to 40 years old) with newly diagnosed type 1 diabetes and randomised them to daily oral treatment with fenofibrate 160 mg or placebo for 52 weeks (in a block design with a block size of 4, assigned in a 1:1 ratio).

View Article and Find Full Text PDF

Background: Heart failure with reduced ejection fraction (HFrEF) remains a significant public health issue, with the disease advancing despite neurohormonal antagonism. Energetic dysfunction is a likely contributor to residual disease progression, and we have previously reported a strong association of plasma metabolite profiles with survival among patients with HFrEF. However, the genetic and biologic mechanisms that underlie the metabolite-survival association in HFrEF were uncertain.

View Article and Find Full Text PDF

Aims/hypothesis: Use of genetic risk scores (GRS) may help to distinguish between type 1 diabetes and type 2 diabetes, but less is known about whether GRS are associated with disease severity or progression after diagnosis. Therefore, we tested whether GRS are associated with residual beta cell function and glycaemic control in individuals with type 1 diabetes.

Methods: Immunochip arrays and TOPMed were used to genotype a cross-sectional cohort (n=479, age 41.

View Article and Find Full Text PDF